Table 1.

Patient characteristics at the beginning of the followup. Values are median (IQR) or % unless otherwise specified.

CharacteristicscDMARD, n = 1400TNFi, n = 3094IFX, n = 642ETN, n = 1245ADA, n = 1207RTX, n = 438p*
Age62 (53–72)54 (45–61)52 (44–59)54 (45–61)55 (47–62)59 (52–67)< 0.001
Female sex697572767677< 0.001
Time from diagnosis, yrs9.4 (5.0–13)11 (6.0–19)11 (5.8–17)11 (5.8–19)12 (6.4–20)15 (8.7–23)< 0.001
Beginning of followup, yr2009 (2008–2010)2006 (2004–2008)2003 (2002–2007)2006 (2004–2009)2006 (2005–2008)2009 (2008–2010)< 0.001
RF-positive657878777888< 0.001
DAS283.2 (2.2–4.3)4.4 (3.2–5.5)4.8 (3.6–5.8)4.2 (3.0–5.3)4.3 (3.2–5.4)4.5 (3.3–5.4)< 0.001
HAQ-DI0.8 (0.28–1.4)1.0 (0.50–1.5)1.1 (0.62–1.7)1.0 (0.50–1.5)1.0 (0.48–1.5)1.1 (0.6–1.7)< 0.001
Prior malignancy5.53.23.03.33.310< 0.001
Hospitalization because of an infection during past 24 mos3.64.04.23.93.97.8< 0.001
Baseline use of MTX755454545641< 0.001
Baseline use of sulphasalazine312222222217< 0.001
Baseline use of HCQ412828282825< 0.001
Baseline use of oral corticosteroids537578757378< 0.001
Prior biologic03112373663> 0.001
Prior TNFi03012363561< 0.001
Prior biologic other than TNFi02.11.62.61.86.4< 0.001
1 prior biologic0255.0322826< 0.001
More than 1 prior biologic06.17.04.67.236< 0.001
Duration of prior biologic treatment ≥ 1.60 yrs0144.4161840< 0.001
  • * Pooled TNFi column excluded from baseline statistical comparison. IQR: interquartile range; cDMARD: conventional disease-modifying antirheumatic drug; TNFi: tumor necrosis factor inhibitors; IFX: infliximab; ETN: etanercept; ADA: adalimumab; RTX: rituximab; RF: rheumatoid factor; DAS28: Disease Activity Score at 28 joints; HAQ-DI: Health Assessment Questionnaire–Disability Index; MTX: methotrexate; HCQ: hydroxychloroquine.